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Introduction: Rheumatoid arthritis (RA) is characterized by enhanced blood vessel development in joint synovium.
This involves the recruitment of endothelial progenitor cells (EPCs), allowing for de novo vessel formation and
pro-inflammatory cell infiltration. Inhibitor of DNA Binding 1 (Id1) is a transcription factor characteristic of EPCs that
influences cell maturation.
Method: Enzyme-linked immunosorbant assay (ELISA) and polymerase chain reaction (PCR) were used to examine
Id1 levels in synovial fluid (SF) and endothelial cells (ECs), respectively. Immunohistology was used to determine the
expression of Id1 in synovial tissue (ST). Human dermal microvascular EC (HMVEC) migration and tube forming
assays were used to determine if recombinant human Id1 (rhuId1) and/or RA SF immunodepleted Id1 showed
angiogenic activity. We also utilized the RA ST severe combined immunodeficient (SCID) mouse chimera to
examine if Id1 recruits EPCs to RA synovium.
Results: ST samples immunostained for Id1 showed heightened expression in RA compared to osteoarthritis (OA)
and normal (NL) ST. By immunofluorescence staining, we found significantly more Id1 in RA compared to OA and
NL vasculature, showing that Id1 expressing cells, and therefore EPCs, are most active in vascular remodeling in the
RA synovium. We also detected significantly more Id1 in RA compared to OA and other arthritis SFs by ELISA, which
correlates highly with Chemokine (C-X-C motif) ligand 16 (CXCL16) levels. In vitro chemotaxis assays showed that
Id1 is highly chemotactic for HMVECs and can be attenuated by inhibition of Nuclear Factor κB and
phosphoinositide 3-kinase. Using in vitro Matrigel assays, we found that HMVECs form tubes in response to rhuId1
and that Id1 immunodepleted from RA SF profoundly decreases tube formation in Matrigel in vitro. PCR showed
that Id1 mRNA could be up-regulated in EPCs compared to HMVECs in response to CXCL16. Finally, using the
K/BxN serum induced arthritis model, we found that EC CXCR6 correlated with Id1 expression by
immunohistochemistry.
Conclusions: We conclude that Id1 correlates highly with CXCL16 expression, EPC recruitment, and blood vessel
formation in the RA joint, and that Id1 is potently angiogenic and can be up-regulated in EPCs by CXCL16.* Correspondence: jhruth@med.umich.edu
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RA is a debilitating inflammatory joint disease in which
microvascular expansion in the joint lining is a charac-
teristic finding. Synovial neovascularization occurs pre-
symptomatically and is critical for disease progression [1].
Expansion of the microcirculation requires either the
proliferation of existent vascular endothelial cells (ECs)
(angiogenesis), or the recruitment from the bone marrow
(BM) of endothelial progenitor cells (EPCs) (vasculogen-
esis) [2]. Recruitment is orchestrated by vessel lumen ex-
pression of adhesion molecules that capture circulating
EPCs [3], and of chemokines that direct EPC migration
into surrounding tissues [4]. Over the past decade, EPCs
have emerged as important regulators of cardiovascular
integrity [5]. However, the specific molecular mechanisms
that mediate EPC recruitment remain poorly understood.
Additionally, little information exists regarding the relative
contribution of EPCs to the synovial neovascularization
that occurs in RA.
EPCs have been identified both in the human mono-
nuclear leukocyte fraction of peripheral blood (PB) [6],
and in their site of origin, the BM [7]. EPCs can be de-
tected in the PB, expressing a variety of cell surface
markers, which identify them as vascular and BM de-
rived. Key EPC markers include vascular endothelial
(VE) cadherin, vascular endothelial growth factor recep-
tor 2 (VEGFR2), CD31low, c-kit and prominin 1/AC133
[8-11]. However, the expression of these markers differs
depending on whether the EPCs are in the BM, PB or in
tissues such as tumors or the RA synovium.
Previous studies have shown EPCs uniquely express
the transcription factor Id1. Id1 is a member of the
helix-loop-helix (HLH) family of transcription factors
and a marker of self-renewal [12]. Inhibition of Id1 in
the BM results in significant EPC linked tumor vascular
defects [9,13]. This strongly suggests that Id1 is a true
marker of EPCs. To this end, the need exists to clearly
identify EPCs in RA tissues, and to better characterize
what exactly governs their recruitment. CXCL16 is a
chemokine known to be very highly expressed in RA tis-
sues [14-16]. Interestingly, human and murine EPCs
have also been shown to express the CXCL16 receptor
CXCR6, suggesting that this ligand-receptor pair might
be a principal factor for EPC recruitment into the RA
joint [17].
We have evidence that EPCs utilize the CXCL16-
CXCR6 ligand-receptor pair for recruitment purposes,
and are associated with Id1 expression in RA. Consider-
ing the known function of the CXCR6 receptor in rela-
tion to recruitment and homing of immune cells in RA
[14], it is reasonable to expect that CXCR6 may also be
involved in the recruitment and homing of Id1 express-
ing mesenchymal stem cells (MSCs) to RA synovium,
likely for the purposes of tissue regeneration and/orvasculogenesis [17]. We show that Id1 is intrinsic to this
process and together with the CXCL16-CXCR6 ligand-
receptor pair, work to bring EPCs from the BM to the
RA joint.
Methods
Rodents
Animal care at the Unit for Laboratory Animal Medicine
(ULAM) at the University of Michigan is supervised by
a veterinarian and operates in accordance with federal
regulations. Severe combined immunodeficient (SCID)
and C57BL/6 mice were obtained from the National
Cancer Institute (NCI). All efforts were made to reduce
stress or discomfort to all animals. All rodents were
given food and water ad libidum throughout the entire
study and were housed in sterile rodent micro-isolator
caging with filtered cage tops in a specific pathogen-free
environment to prevent infection. Approval to use ani-
mals for all parts of this study was obtained from the
ethics committee at the University of Michigan Commit-
tee on the Use and Care of Animals (UCUCA).
K/BxN serum-induced arthritis model
K/BxN breeder mice were provided by Drs. Mathis and
Benoit. To generate arthritic K/BxN mice, K/B positive
mice were crossed with NOD/LTj mice as previously de-
scribed [18]. Naïve wild type (Wt) and CXCR6 gene
knockout (CXCR6−/−) mice at the age of five to seven
weeks were injected with 150 μl of K/BxN serum i.p.,
and this was considered to be Day 0 of arthritis. Another
injection of 150 μl of K/BxN serum followed on Day 2.
Robust arthritis with severe swelling of the joints typic-
ally developed on Day 5. Mouse ankles were harvested
for histology typically by Day 12.
Isolation of EPC CD34+ cells from cord blood
Human EPCs were isolated from cord blood from
granulocyte-colony stimulating factor (G-CSF) mobilized
leukopheresis samples on the basis of CD133 expression,
using an antibody coupled magnetic bead cell isolation
system (Stem Cell Technologies, Vancouver, BC, Canada).
Human umbilical cord blood was collected by the method
of Moore et al. [19] as previously described [20]. To con-
firm purity of the EPCs, isolated cell populations were
subjected to flow cytometry analysis as described previ-
ously [21,22]. EPCs with appropriate cell markers (CD34+,
CD133+, CD14−) were used in chimeras and related
in vitro studies.
Neutralization of Id1 in RA SFs
RA SFs were pre-incubated either with mouse anti-
human Id1 antibody (Abcam, Cambridge, MA, USA) or
with an equivalent amount of a corresponding control
antibody (non-specific mouse IgG) for two hours at 4°C.
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pore, Billerica, MA, USA), and rotated overnight at 4°C.
Samples were centrifuged briefly to pellet the Id1/anti-
body/Protein A/G complex and the Id1 depleted SFs
were collected.ELISA for Id1 and CXCL16
Rheumatoid factor (RF) was depleted from human SFs
using anti-human IgM (μ-chain specific) agarose antibody
(Sigma-Aldrich, St. Louis, MO, USA). Levels of Id1 were
measured using 96-well plates. RA, OA and other disease
SFs, and Id1 as a standard were coated in duplicate for
one hour. The plates were washed with wash buffer and
coated with blocking buffer. Mouse anti-human Id1 anti-
body (Abcam) in blocking buffer was added for one
hour. Subsequently, biotinylated goat anti-mouse antibody
(Vector Labs, Burlingame, CA, USA) and streptavidin-
HRP (BD Biosciences, San Jose, CA, USA) were added,
and the concentration in samples was measured at
450 nm after developing the reaction with tetramethylben-
zine substrate (TMB, Sigma-Aldrich). For the CXCL16
ELISA, 96-well plates were coated with rabbit anti-human
CXCL16 (PeproTech, Rocky Hill, NJ, USA). SFs and
rhuCXCL16 (PeproTech) as a standard were added. Bio-
tinylated rabbit anti-human CXCL16 antibody (PeproTech)
was used to detect CXCL16 using a streptavidin-HRP, with
TMB. The concentration in each sample was measured at
450 nm.Immunohistologic analysis
Tissue slides were fixed in cold acetone for 20 minutes.
Following incubation with 3% H2O2 for five minutes to
block endogenous peroxidase, STs were blocked with
20% fetal bovine serum (FBS) and 5% goat serum in
phosphate-buffered saline (PBS) at 37°C for one hour,
and then incubated with mouse anti-human Id1 anti-
body (Abcam, 10 μg/ml), rabbit anti-mouse Id1 antibody
(Cal Bioreagents, San Mateo, CA, USA) or purified non-
specific IgG for one hour at 37°C in blocking buffer. The
ST samples were washed with PBS, and a 1:200 dilution
in blocking buffer of biotinylated goat anti-mouse or
anti-rabbit antibody was added and incubated for an
additional 30 minutes at 37°C. After washing, antibody
binding was detected using a Vectastain ABC Elite kit
(Vector Labs) and the chromogen 3,3′-diaminobenzi-
dine (DAB) (Vector Labs). ST samples were counter-
stained with Harris hematoxylin. Staining was evaluated
by a pathologist who was blinded with regard to the
sample group. Slides were examined for cellular immu-
noreactivity, and cell types were distinguished based on
their characteristic morphology. The percentage of cells
expressing Id1 was analyzed and graphed.Immunofluorescence (IF)
The slides were fixed in cold acetone for 30 minutes.
The STs were blocked with 5% donkey serum and 20%
FBS in PBS at 37°C for one hour, and then incubated
with mouse anti-human Id1 antibody (Abcam, 10 μg/ml)
and rabbit anti-human von Willebrand factor (vWF) anti-
body (DAKO, Carpinteria, CA, USA), or purified nonspe-
cific mouse and rabbit IgG for one hour at 37°C in
blocking buffer. The ST samples were washed with PBS,
and a 1:200 dilution in blocking buffer of fluorescent con-
jugated donkey anti-mouse and donkey anti-rabbit anti-
body was added and incubated for an additional one hour
at 37°C.
RNA extraction and quantitative RT-PCR
Total RNA was isolated from HMVECs and EPCs using
RNAeasy mini RNA isolation kits in conjunction with
QIAshredders (Qiagen, Valencia, CA, USA) following
the manufacturer’s protocol. Following isolation, RNA
was quantified and checked for purity using a spectro-
photometer (Nanodrop Technologies, Wilmington, DE,
USA). cDNA was then prepared using a Verso cDNA kit
(Thermo Fisher Scientific) as per the manufacturer’s
protocol. Quantitative PCR (qPCR) was performed using
Platinum SYBR Green qPCR SuperMix-UDG (Life Tech-
nologies, Carlsbad, CA, USA) following the manufac-
turer’s protocol. The primer pairs used were based on
published sequences. Diluted cDNA was mixed with
Platinum SYBR green qPCR SuperMix-UDG, forward
and reverse primers specific for each gene (10 μM final
concentrations), and incubated at the following cycles;
50°C for 2 minutes, 95°C for 2 minutes and 40 cycles of
95°C for 30 sec, 55°C for 30 sec and 68°C for 30 sec
using an ABI Prism 7500 sequence detection system
(Applied Biosystems). The primers for human Id1 [23],
are forward: AGAACCGCAAGGTGAGCAA and reverse:
CCAACTGAAGGTCCCTGATGTAG. The primers used
for β-actin were the same as we used previously [24], and
are forward: GCTAGGCAGCTCGTAGCTCT and re-
verse: GCCATGTACGTTGCTATCCA. All samples were
run in duplicate.
HMVEC chemotaxis to Id1
HMVECs (BioWhittaker, Walkersville, MD, USA) were
maintained in growth factor complete endothelial basal
media (EBM) supplemented with 5% FBS. Cells were be-
tween passages 7 and 10, and did not display discernable
phenotypic changes when observed before each assay.
Cells were maintained at 37°C and 5% CO2. HMVEC
migration in vitro was tested using a modified 48-well
Boyden chemotaxis chamber (Neuroprobe, Cabin John,
MD, USA). HMVECs (1 × 106 cells/ml EBM + 0.1% FBS)
were plated in the bottom wells of the chambers with a
polyvinylpyrolidone-free polycarbonate filter (8-μm pore
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were inverted and incubated in a humidified incubator
with 5% CO2/95% air at 37°C for two hours, allowing
HMVECs to attach to the membrane. The chambers
were inverted again and Id1 was added at different con-
centrations, with PBS, or basic fibroblast growth factor
(bFGF, 60 nM) used as negative and positive controls,
respectively. After incubation for two hours at 37°C, the
membranes were removed, fixed in methanol for one
minute, and stained with Diff-Quick (VWR Inter-
national, West Chester, PA, USA). Cell migration was
determined in quadruplicate and analyzed in three high-
power 40X fields per well. The experiment was per-
formed four times. Data are expressed as the number of
cells migrating per well.
Signal inhibited chemotaxis assay
To determine which kinases were required for Id1 me-
diated HMVEC chemotaxis, cells were incubated with
chemical signaling inhibitors. HMVECs were pre-
incubated with chemical signaling inhibitors for one
hour prior to the assay, and the inhibitors were present
in the lower chamber with the HMVECs during the
assay. The following inhibitors were purchased from
and used at concentrations recommended by Calbio-
chem (La Jolla, CA, USA): PD98059 (10 μM Erk1/2
inhibitor), PDTC (100 μM nuclear factor kappa B
(NFκB) inhibitor), LY294002 (10 μM PI3K inhibitor),
SB203580 (10 μM p38 MAPK inhibitor) and PP2 (1 μM
Src inhibitor).
Matrigel tube formation assay
Matrigel tube formation assay using growth factor-reduced
Matrigel (BD Biosciences) was performed. HMVECs were
seeded in Labtek chamber slides on growth factor reduced
Matrigel (Becton Dickinson, Bedford, MA, USA) at a dens-
ity of 1.6 × 104 cells per chamber. The test substances used
were rhuId1 (1 and 10 nM), bFGF (60 nM, R&D Systems,
Minneapolis, MN, USA; positive control) and PBS (nega-
tive control). The treated HMVECs (1.8 × 104 cells/400 μl)
were plated on Matrigel in the presence of Id1, bFGF or
PBS for six hours at 37°C. Photographs (100×) were taken
and tubes were counted by a blinded observer. Tubes were
defined as elongated connecting branches between two
identifiable HMVECs. SFs were diluted 1:100 with PBS.
Matrigel tube formation assay was performed using SFs
and PBS. Photographs (100×) were taken and tubes were
counted by a blinded observer.
RA ST SCID mouse chimera
The backs of six- to eight-week-old SCID mice (NIH/
NCr) were shaved and graft beds prepared (1 × 1 ×
0.05 cm). A single graft was implanted per animal (ap-
proximately 0.5 cc). Human RA STs were implanted andtransplants sutured while mice were anesthetized. Grafts
were allowed to “take” and used at approximately four
weeks after surgery when animals did not experience
gross evidence of inflammation other than the antici-
pated neovascularization. Once grafts took, 2.5 × 105
fluorescently dye-tagged (PKH26 dye, Sigma-Aldrich, St.
Louis, MO, USA) EPCs were injected i.v. into mice while
they were receiving simultaneous intragraft injections of
RA SF (100 μl) that was either “sham” immunoneutra-
lized with non-specific IgG or immunoneutralized with
the specific antibody to human Id1. For some experi-
ments, RA ST SCID mouse chimeras were injected with
2.5 × 105 fluorescently dye-tagged human EPCs while re-
ceiving simultaneous injections of either human Id1 (10
nM) or PBS (100 μl). EPCs were allowed to circulate for
72 hours. Grafts were then harvested, cryosectioned and
examined using a fluorescence microscope. Human RA
ST grafts as well as murine organs, such as lymph nodes
(LNs), spleen, kidney, heart, lung, liver and brain, were
harvested at the time of sacrifice. These tissues were
examined for non-specific EPC recruitment to non-
targeted tissues to ensure that adoptively transferred
EPCs were recruited only to the engrafted synovium. All
engrafted STs, as well as various organs, were snap-
frozen in liquid nitrogen, and stored at −80°C until
further processing.
Statistical analysis
Results are expressed as the mean ± standard error of
the mean (SEM). Data were analyzed using a Student’s t-
test. P-values less than 0.05 were considered significant.
Results
ELISA for Id1 and CXCL16 on SFs
Id1 is expressed and secreted in SFs, and can be mea-
sured in RA, OA and other disease SFs (two gout, one
seronegative spondylitis, and one lupus SF). As shown,
Id1 is elevated in RA compared to OA and other disease
SFs (Figure 1A), taken from a patient population around
the same point in time to ensure that we controlled for
any possible effects on Id1 and CXCL16 concentration
measurements from the storage conditions. Similarly for
CXCL16, 96-well plates were coated with rabbit anti-
human CXCL16 (PeproTech). The identical RA SFs
were used for Id1 and CXCL16 measurements for the
correlation studies. We found that soluble Id1 highly
correlates with CXCL16 in RA SF (Figure 1B), indicating
that CXCL16 and EPC migration are linked in RA SF
(Pearson’s correlation coefficient r = 0.75; n = 20).
mRNA extraction and quantitative RT-PCR
Total RNA was isolated from stimulated (tumor necrosis
factor-alpha (TNF-α) or CXCL16) or non-stimulated
HMVECs and EPCs. The data are presented as fold
ADC
B
Figure 1 Id1 and CXCL16 are linked in RA SF and at the level of transcription in EPCs. An ELISA was developed to detect Id1 in synovial
fluids (SFs) taken from rheumatoid arthritis (RA), osteoarthritis (OA) and patients with other arthritic disorders, including gout, seronegative
spondyloarthritis and systemic lupus erythematosus. A) The ELISA showed that Id1 was found in SFs of other diseases (n = the number of
patients = 4, 13.8 (mean) ± 0.9 (standard error of mean (SEM)) ng/ml) and was significantly higher in RA SFs (n = 13, 19.4 ± 1.3 ng/ml), and OA SF
(n = 9, 14.9 ± 1.4 ng/ml), all of which were P <0.05 (n = number of patients). B) CXCL16 was measured in the same samples as Id1, and correlated
with Id1 expression in RA SF (r = 0.75 Pearson’s Correlation Coefficient (P <0.05, n = number of patients). C) Total RNA was isolated from human
dermal microvascular endothelial cells (HMVECs) and endothelial progenitor cells (EPCs). Following isolation, RNA was quantified and checked for
purity using a spectrophotometer and made into cDNA and amplified in a thermocycler (40 cycles). As shown, tumor necrosis factor-alpha
(TNF-α) did not affect Id1 mRNA levels in EPCs, and reduced the number of Id1 transcripts in HMVECs. D) CXCL16 stimulation elevated Id1
mRNA expression in EPCs but not HMVECs, indicating that CXCL16 and Id1 are associated at the level of transcription in EPCs but not mature ECs
(n = number of independent experimental replicates).
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serve as the control. TNF-α did not affect Id1 mRNA in
EPCs, but significantly reduced the number of Id1
transcripts in HMVECs compared to NS HMVECs
(Figure 1C). In addition, there was a significant reduc-
tion of Id1 transcripts between HMVECs and EPCs
stimulated with TNF-α. We also found significantly ele-
vated Id1 mRNA expression in EPCs compared to
HMVECs when cells were stimulated with CXCL16,
and that CXCL16 up-regulates Id1 expression in EPCs,
but not HMVECs, indicating that CXCL16 and Id1are associated at the level of transcription in EPCs
(Figure 1D).
Histology for Id1 was performed on RA, OA and NL ST
sections
Id1 is highly expressed in the vasculature of RA ST, but
less so in OA or NL ST, suggesting that the micro-
environment of the RA joint either facilitates Id1 expres-
sion or is favorable to EPC migration (Figure 2A). The
results are graphed and show that Id1 is clearly present on
a higher percentage of ECs in RA compared to OA and
DA B
C
Figure 2 IF was performed on RA, OA, and NL ST sections: A) For IF histology, samples were incubated with mouse anti-human Id1
antibody then followed with a fluorescent conjugated secondary antibody. Samples were stained with DAPI (blue) and images merged. Id1
expression is clearly shown in green (images were taken at 400×). IHC was also performed on RA, OA, and NL ST sections as described. As shown,
Id1 could be seen up-regulated in RA vascular tissue by IF staining and IHC. B) The percentage of cells expressing Id1 were analyzed on ECs with
a significantly higher percentage of Id1 expressing ECs in RA compared to NL and OA ST (n = number of patients). C) For merged IF histology,
samples were incubated with mouse anti-human Id1 and rabbit anti-human vWF antibodies. This was followed by fluorescent conjugated
secondary antibodies and images were merged. Id1 expression is clearly shown in red and vessels as defined by vWF expression are shown in
green (images taken at 400×). Merged vessel regions shown in yellow are due to Id1 expressing EPCs. D) The percentages of Id1 positive tubes
in each of the tissues were calculated and graphed. Id1 containing vasculature was significantly higher in RA compared to NL and OA ST
(400×, n = number of patients).
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but the highest amounts of both vasculature and Id1 ex-
pression can be seen in RA compared to OA and NL ST
(shown embedded in yellow; see arrow; Figure 2C). Images
were taken at 400× and merged. The percentage of Id1positive tubes was calculated and expressed in the graph.
Significantly higher percentages of Id1 expressing tubes
were identified in RA compared to OA and NL ST, indi-
cating that vasculogenesis due to EPC migration to syno-
vium is elevated in RA synovium (Figure 2D).
AB
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HMVEC chemotaxis assays to rhuId1 (1 to 100 nM)
were performed. Readings represent the number of cells
migrating through the membrane (the sum of three
high-power fields (400×)/well, averaged for each quad-
ruplicate well). Id1 displayed potent chemotactic activ-
ity for HMVECs at the three doses tested (1, 10 and 100
nM), but was most active at 10 nM (Figure 3A). We ex-
amined HMVEC signaling pathways in response to Id1
using signaling inhibitors and performed HMVEC
chemotaxis assays at the peak concentration of Id1
chemotactic activity (10 nM). We found that PDTC
(NFκB inhibitor) and Ly (PI3K inhibitor) significantly
reduced HMVEC migration towards Id1. The other in-
hibitors used (PD, MAPK inhibitor; SB, p38 inhibitor;
PP2, Src inhibitor) had no effect upon Id1 HMVEC
chemotaxis (Figure 3B).Capillary morphogenesis assay shows that Id1 is
angiogenic
HMVECs formed tubes to Id1 at 10 nM, which was the
peak concentration for HMVEC chemotactic activity
(Figure 4A). We then measured Id1 in the SFs pre- and
post-Id1 neutralization, and as shown, anti-Id1 antibody
effectively neutralized Id1 activity in the SFs. RA SF de-
pleted of Id1 showed less HMVEC tube forming activity
compared to “sham”, IgG depleted SFs. Photographs
(100×) were taken and tubes were counted by a blinded
observer (Figure 4B).Figure 3 Chemotaxis: to determine the kinases required for Id1
mediated HMVEC chemotaxis, cells were incubated with
chemical signaling inhibitors. Human dermal microvascular
endothelial cells (HMVECs) were pre-incubated with chemical
signaling inhibitors for one hour prior to the assay, and the inhibitors
were present in the lower chamber with the HMVECs during the
assay. The following inhibitors were purchased from and used at
concentrations recommended by Calbiochem (La Jolla, CA):
PD98059 (10 μM Erk1/2 inhibitor), PDTc (100 μM NFκB inhibitor),
LY294002 (10 μM PI3K inhibitor), SB203580 (10 μM p38 MAPK
inhibitor) and PP2 (1 μM Src inhibitor). HMVEC migration assays were
performed by placing cells in a 48-well neuroprobe microchemotaxis
chamber. A) HMVECs were chemotactic for Id1 at physiologically
relevant concentrations of Id1 (1, 10 and 100 nM, n = number of
independent experimental replicates). B) We examined HMVEC
signaling pathways to Id1 using signaling inhibitors, and performed
HMVEC chemotaxis assays at the peak concentration of Id1
chemotactic activity (10 nM). We found that PDTc (NFκB inhibitor)
and Ly (PI3K inhibitor) significantly reduced HMVEC migrationEPCs migrate to Id1 in the RA ST SCID mouse chimera
Fluorescently dye-tagged EPCs were administered i.v. into
mice receiving simultaneous intragraft injections of RA SF
that was either “sham” immunoneutralized with non-
specific IgG or immunoneutralized with specific antibody
to human Id1. Approximately 50% fewer EPCs migrated to
engrafted RA ST injected with RA SF depleted of Id1 com-
pared to sham depleted injected RA SF (Figures 5A, B).
RA ST SCID chimeric mice injected intragraft with Id1
(10 nM) compared to PBS had significantly elevated EPC
migration to the engrafted RA ST, showing less than 50%
fewer EPCs migrating to engrafted RA ST injected with
PBS alone (Figure 5C). Also shown is a picture of engrafted
RA ST in the SCID mouse chimera showing a viable RA
ST graph (Figure 5D).towards Id1. The other inhibitors used had no effect upon Id1 HMVEC
chemotaxis (n = number of independent experimental replicates).Id1 expression is elevated in Wt, but not CXCR6−/− K/BxN
serum-induced mice
Wt and CXCR6−/− mice were induced with K/BxN serum,
joints harvested and tissue sections immunostained for
Id1. Day 12 Wt mice show clear expression of Id1 positive
ECs, whereas CXCR6−/− mice do not (400×, Figure 6A).The results are graphed and show that day 0 and 12 Wt
mice have Id1 expressing EPCs in joint tissue, but Id1
positive cells were not detected in Day 12 K/BxN serum-
induced CXCR6−/− mice (Figure 6B).
AB
Figure 4 (See legend on next page.)
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Figure 4 In vitro Matrigel tube formation assay. A) Matrigel tube formation assay using growth factor-reduced Matrigel (BD Biosciences) was
performed. The test substances used were recombinant human Id1 (rhuId1) (1 and 10 nM), basic fibroblast growth factor (bFGF) (60 nM, R&D
Systems, positive control) and phosphate-buffered saline (PBS) (negative control). The treated human dermal microvascular endothelial cells
(HMVECs) (1.8 × 104 cells/400 μl) were plated on Matrigel in the presence of Id1, bFGF or PBS for six hours at 37°C. Photographs (100×) were taken
and tubes were counted by a blinded observer. Tubes were defined as elongated connecting branches between two identifiable HMVECs. A)
HMVECs formed tubes to Id1 at 10 nM (the concentration for peak HMVEC chemotactic activity for HMVECs, n = number of independent
experimental replicates). B) Rheumatoid arthritis (RA) synovial fluid (SF) was pre-incubated with mouse anti-human Id1 antibody (Abcam) for two
hours at 4°C. RA SFs were added in the Protein A agarose beads and were rotated at 4°C overnight. The next day, the samples were spun down
and SFs collected. SFs were diluted 1:100 with PBS. We then measured Id1 in the SFs pre- and post-Id1 neutralization, and as shown, effectively
eliminated Id1 from the SFs. RA SF depleted of Id1 showed less HMVEC tube forming activity compared to “sham”, IgG depleted SFs. Photographs
(100×) were taken and tubes were counted by a blinded observer (n = number of independent experimental replicates).
A B
C D
Figure 5 RA ST SCID mouse chimera. After a four-week engraftment period, mice were injected i.v. with 2.5 × 105 fluorescently dye-tagged
human endothelial progenitor cells (EPCs) while receiving simultaneous intragraft injections of rheumatoid arthritis (RA) synovial fluid (SF) (100 μl)
that was either “sham” immunoneutralized with non-specific IgG or immunoneutralized with specific antibody to human Id1. In some
experiments, RA synovial tissue (ST) SCID chimeric mice received dye-tagged EPCs while receiving simultaneous intragraft injections of human Id1
(10 nM) or PBS. A) Section from a SCID mouse injected with Id1 or sham immunodepleted RA SF showing significantly elevated EPC migration to
the engrafted RA ST injected with “sham” immunodepleted RA SF. B) Approximately 50% fewer EPCs migrated to engrafted RA ST injected with
Id1 neutralized from RA SF compared to sham injected RA SF (n = 10 sections from five mice (that is, two sections/mouse)). C) Less than 50%
fewer EPCs migrated to engrafted RA ST in chimeric mice when injected intragraft with phosphate-buffered saline (PBS) compared to Id1 (n = 10
sections from five mice (that is, two sections/mouse)). D) Engrafted RA ST in the SCID mouse chimera.
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Neovascularization occurs by one of two mechanisms:
angiogenesis, the replication and reorganization of pre-
existing microvascular ECs [25], or by vasculogenesis,
the recruitment of EPCs that subsequently incorporate
into the existent tissues and differentiate into mature
functional ECs [26]. However, the lack of a single marker
to unambiguously track EPCs has led to several recent
studies failing to identify these cells in specific mouse
tumor models [10,11,27,28]. As a result, it is argued that
EPCs may not be a viable target for RA therapy as these
cells have not been found in appreciable numbers in
inflamed synovium. However, these same findings
raised significant concerns as to whether the same EPC
population is being truly monitored in vivo, and has
imposed tremendous limitations on the assessment of
the biological function of EPCs, as well as their poten-
tial use as a therapeutic strategy targeting neovascula-
ture in RA tissues [29].A
B
Figure 6 Id1 expression is elevated in Wt, but not CXCR6−/− K/BxN se
with K/BxN serum and joint tissue sections were immunostained for Id1. A
cells (ECs), whereas CXCR6−/− mice do not. B) The results are graphed and
progenitor cells (EPCs) in joint tissue, but Id1 positive cells were not detect
from 10 mice for the Wt groups, and n = 10 sections from four mice in theNotably, RA patients show increased numbers of cir-
culating EPCs that correlate with Disease Activity Scores
using 28 joint counts (DAS28), signifying that EPCs are
likely elevated and recruited to inflamed tissues for the
purposes of synovial vasculogenesis [30]. Additionally,
growing evidence has suggested that EPCs contribute to
the homeostasis of the physiologic vascular network [5],
as well as contribute to vascular remodeling of RA syno-
vium by recruiting BM derived circulating EPCs [20].
We believe that analysis of EPC mediated migration
using Id1 as a selective and unique EPC marker may be
an intriguing strategy for identifying and targeting EPC
vascular integration during the course of active arthritis.
Histologic analysis of ST revealed that Id1 is highly
expressed in the vasculature of RA ST, but less so in OA
or NL ST, suggesting that the micro-environment of the
RA joint either facilitates Id1 expression and/or is favor-
able for EPC migration. We used fluorescence histology
to examine the percentage of blood vessels containingrum-induced mice. Wild type (Wt) and CXCR6−/− mice were induced
) Day 12 Wt mice show clear expression of Id1 positive endothelial
show that day 0 and 12 Wt mice have Id1 expressing endothelial
ed in Day 12 K/BxN serum-induced CXCR6−/− mice (n = 10 sections
CXCR6−/− group (400×)).
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age of Id1 containing blood vessels in RA compared
to OA and NL STs. These findings are in complete
agreement with those of Sakurai et al., who showed
substantial expression of Id1 and Id3 in RA compared
to OA synovium at the protein and transcriptional
levels [31].
One of the many interesting features of Id1 is its ability
to not only inhibit genes related to cell maturity and
growth, but to equally repress inhibitors of angiogenesis.
Previous studies showed that Id1 regulates angiogenesis
through transcriptional repression of thrombospondin-1
[32]. It was subsequently shown that Id1 can also repress
p21 expression to control EPC growth and maturation in
the BM. Because of the ability of Id1 to down-regulate ex-
pression of these potent repressors, it was reported that
Id1 can function as an effective pro-angiogenic mediator
produced by EPCs and pluripotent stem cells [33]. This
idea was reinforced by reports identifying Id1 and Id3 as
negative regulators of pluripotent stem cell maturation
[34], and supported the notion that Id1 is uniquely
expressed in progenitor cells. These findings also
pointed to Id1 as a selective marker for progenitor
cells that could be used to identify EPCs in tissues
characterized by extensive vascular remodeling. Gao
et al. subsequently showed that it was possible to
identify, track and target BM-derived EPCs in vivo
using a mouse model of pulmonary metastasis by way
of Id1 expression. The authors went on to show that
targeting EPCs in this way blocked EPC mobilization,
caused angiogenesis inhibition, impaired the spread of
metastasis, and increased the survival of tumor bear-
ing mice [9,29].
We surmised that Id1 could also be used to identify
EPCs in RA tissues, and examined if Id1 could be
expressed and secreted as well as exhibit angiogenic ac-
tivity after exiting the cell. We show that Id1 can be se-
creted, is highly expressed in RA SF, and can be
correlated with CXCL16 expression. Indeed, approxi-
mately 56% of the variability of CXCL16 in RA SFs can
be accounted for by Id1, which is relatively large consid-
ering the numerous angiogenic factors in the RA joint
[35]. This indicates that CXCL16 (therefore, CXCR6 ex-
pressing cells) is linked with Id1 expression (therefore,
EPCs) in RA tissues. We measured Id1 in RA SFs and
compared this to the levels found in OA SFs as well as
SFs from patients with other diseases. The OA SFs serve
as non-inflammatory, non-autoimmune controls for the
RA SFs. Although not ideal, we do not have access to
NL SFs as these are not available. For this reason, we
have used OA SFs for comparison of soluble pro-
inflammatory mediators (for example, cytokines and
chemokines) in many previous studies [14]. It should
also be noted that the heterogeneity of the SFs from the“other disease” group was intended to show that the Id1
levels in OA SFs and SFs from a diverse patient popula-
tion can be used together to verify that Id1 is uniquely
elevated in RA SF, and can be correlated to RA SF
CXCL16 expression.
Ling et al. previously reported that Id1 protein can be
regulated by TNF-α in prostate cancer cell lines. They
found that exposure to TNF-α in two different cell lines
(DU145 and PC-3) resulted in a rapid and significant
down-regulation of Id1 protein [36]. We show that Id1
mRNA transcripts can be detected in HMVECs and
EPCs, and that CXCL16, but not TNF-α, can up-
regulate Id1 expression in EPCs. It is important to point
out that although we found Id1 mRNA in both
HMVECs and EPCs, it was only actively transcribed in
EPCs upon CXCL16 stimulation. Id1 mRNA expression
in mature cells, such as HMVECs, is likely due to the re-
markable stability of Id1 mRNA, over eight-fold higher
than comparable mRNAs in induced pluripotent stem
cells [37]. We also found that TNF-α destabilized Id1
mRNA in HMVECs, but not EPCs, consistent with pre-
vious reports [36]. This raises the possibility that TNF-α
and CXCL16 activate specific mRNA binding proteins in
ECs and EPCs, that may bind 3′ untranslated regions
(UTRs) effecting Id1 mRNA stability, in a similar way to
that showed previously with granulocyte macrophage-
colony stimulating factor (GM-CSF) and ionophore in
3D10 cells [38]. It is tempting to speculate that as a pro-
genitor cell begins to mature in the RA synovium, locally
expressed cytokines, such as TNF-α and CXCL16, may
affect Id1 stability and expression, thereby permitting
the EPC to mature and incorporate into the existing vas-
culature in the RA joint.
We next examined the possibility that secreted Id1
could recruit HMVECs in vitro. Id1 effectively recruits
HMVECs in a dose-dependent manner that can be inhib-
ited by NFκB and PI3K signaling inhibitors. This demon-
strates that mature ECs actively bind Id1 (indicating a
receptor), and induce signaling pathways. HMVECs also
respond to Id1 in a Matrigel tube forming assay. At the
same concentrations, we observed chemotaxis (1 and 10
nM), HMVECs made extensive networks of tubes in
response to Id1. In addition, diluted RA SF also had
a similar effect on HMVECs in Matrigel, but was re-
versed with removal of Id1 in four out of five RA SFs
examined. To further explore the possibility that Id1
was a potent mediator of vasculogenesis, we looked
at its ability to recruit EPCs to RA ST in the SCID
mouse chimera system. We show that Id1 is a potent
recruitment factor for EPCs, and that RA SF depleted
of Id1 lost approximately 50% of its EPC recruitment
activity in vivo.
To date, stromal derived factor-1α (SDF-1α)/CXCL12
and its receptor CXCR4 have been acknowledged to be
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ity. However, the expression of SDF-1/CXCL12 is compara-
tively much lower in RA SF to that of CXCL16 [14,39].
Interestingly, a Fluorescence Activated Cell Sorter (FACS/
flow cytometry) study reported high percentages (96 ± 2%;
mean ± SEM) of primary BM-derived murine MSCs ex-
pressing CXCR6, but not CXCR4, on their cell surface.
Notably, CXCR6 and CXCR4 were equally expressed on a
high proportion (95 ± 1%) of human BM derived MSCs
[17]. With this in mind, we stained the joint tissues of Wt
and CXCR6−/− K/BxN serum-induced mice for Id1. We ini-
tially found that Day 0 Wt mice show low levels of EC
staining for Id1, which was elevated by Day 12. However,
Day 12 CXCR6−/− mice had significantly reduced arthritis
and vasculature (data not shown) and completely lacked
EC staining for Id1, showing that Id1 and the CXCL16-
CXCR6 ligand-receptor pathway are linked and work to-
gether to recruit EPCs from the BM to the synovium.
Before use in the K/BxN serum transfer arthritis studies,
the CXCR6−/− mice were backcrossed onto the C57BL/6
background for more than 10 generations, making the
C57BL/6 mouse the natural control for these experiments.
We found that healthy mice bred on the C57BL/6 back-
ground do not express appreciable amounts of Id1. We
should also note that the expression of Id1 is generally
very low in joint tissues in the K/BxN serum transfer arth-
ritis model, apart from peak arthritis times (days 5 to 12).
This is likely because it takes significant time for vascula-
ture to develop in joint tissues of arthritic mice, even when
using a potent acute model of arthritis like K/BxN. This is
due in part because BM derived EPCs are required to mi-
grate to the joints and become embedded into the devel-
oping microvasculature. This is the reasoning behind
looking at Day 12 of arthritis induction (that is, close
enough to peak arthritis but before the joint swelling/in-
flammation resolves).
We recently showed a correlation among CXCR6 ex-
pression, arthritis development and angiogenesis in mice
using the K/BxN serum transfer model. We showed that
deletion of CXCR6 (the only known receptor for CXCL16)
prevents arthritis development, severity and joint tissue
vascularity in mice in response to K/BxN serum [40].
Using the same mice and model, we now show that Id1 is
markedly down-regulated in the joints of mice lacking
CXCR6. In our previously published study, we demon-
strated that the CXCR6-CXCL16 receptor-ligand pair is
actively involved in recruiting EPCs to RA ST [40]. Be-
cause EPCs express CXCR6 and respond to CXCL16
in vivo, we hypothesized that Id1 expressing EPCs could
be found in the neovasculature of inflamed joint tissue,
and that this process could be inhibited by disruption of
the CXCR6-CXCL16 receptor-ligand pair.
We believe that studies such as this will lead to a bet-
ter understanding of the mechanisms that regulate EPCrecruitment and differentiation into mature ECs. EPC re-
cruitment processes that regulate neovascularization are
relevant to diverse clinical scenarios, from inhibiting RA
and tumor progression to replenishing the blood supply of
ischemic hearts. In some of these disease states, such as
myocardial damage, the favorable end goal is to find
means to enhance the contribution of EPCs to new blood
vessel formation, with the desired result of revitalizing the
blood supply to damaged and imperfectly functioning tis-
sues. In the case of tumorigenesis and RA, the opposite ef-
fect (that is, inhibiting or preventing EPC dependent
vascular expansion), in an effort to starve the affected tis-
sues and thus delay or reverse expansion of invasive tis-
sues, is the preferred effect. With a clearer understanding
of the biological underpinnings that guide EPCs to the
microcirculatory beds of inflamed or angiogenic tissues,
we might be able to take advantage of EPC homing in RA
by targeting EPC chemokine receptors, such as CXCR6,
or by using such cells as vehicles for the delivery of biotox-
ins or of gene therapy agents that have anti-inflammatory
activity, cause neovessel obliteration, and/or suppress syn-
ovial proliferation. We show herein that CXCL16 and Id1
are linked and central to EPC recruitment in RA. We also
show that Id1 can be secreted and induce angiogenic ac-
tivity in mature ECs (HMVECs). This indicates that Id1 is
not only self-regulatory in EPCs, but after secretion, can
induce potent angiogenic responses.
Conclusion
Our data indicate that Id1 can be secreted into the RA
SF and correlate with CXCL16 expression. In addition,
CXCR6−/− arthritic mice have markedly reduced Id1 ex-
pression in the K/BxN serum transfer model of arthritis.
We also found that Id1 is potently angiogenic, and can
be up-regulated in HMVECs and EPCs by TNF-α and,
especially, CXCL16. These results indicate that CXCL16
can be highly correlated with Id1 expression, and that
Id1 is active in EPC recruitment and blood vessel forma-
tion in the RA joint.
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